June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
InflaMab: A novel NLRP3 Inflammasome inhibitor provides neuroprotection in a mouse model of glaucoma
Author Affiliations & Notes
  • Melody Chemaly
    Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Massachusetts, United States
    Northern Ireland Centre for Stratified Medicine, School of Biomedical Sciences, Ulster University, United Kingdom
  • Anitha Krishnan
    Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Massachusetts, United States
  • Anthony J Bjourson
    Northern Ireland Centre for Stratified Medicine, School of Biomedical Sciences, Ulster University, United Kingdom
  • Aaron Peace
    Northern Ireland Centre for Stratified Medicine, School of Biomedical Sciences, Ulster University, United Kingdom
    Cardiology Department, Western Health and Social Care Trust, Altnagelvin Hospital, Londonderry, United Kingdom
  • Meredith S Gregory-Ksander
    Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Massachusetts, United States
  • Victoria McGilligan
    Northern Ireland Centre for Stratified Medicine, School of Biomedical Sciences, Ulster University, United Kingdom
  • Footnotes
    Commercial Relationships   Melody Chemaly, None; Anitha Krishnan, None; Anthony J Bjourson, None; Aaron Peace, None; Meredith Gregory-Ksander, (PCT/EP2019/074744) (P); Victoria McGilligan, (PCT/EP2019/074744) (P)
  • Footnotes
    Support  Invest Northern Ireland, RPB international collaborators award
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 2365. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Melody Chemaly, Anitha Krishnan, Anthony J Bjourson, Aaron Peace, Meredith S Gregory-Ksander, Victoria McGilligan; InflaMab: A novel NLRP3 Inflammasome inhibitor provides neuroprotection in a mouse model of glaucoma. Invest. Ophthalmol. Vis. Sci. 2020;61(7):2365.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Recent evidence shows an essential role for NLRP3 inflammasome activation in the pathogenesis of glaucoma and we previously reported that NLRP3 knockout mice were protected from axon degeneration and death of RGCs in an inducible mouse model of glaucoma. These data support pharmacologic inhibition of NLRP3 as a potential neuroprotective therapy in glaucoma. However, the short half-life of the currently available small molecule inhibitors of NLRP3 make them poor candidates for local intravitreal administration, the ideal route of administration for glaucoma. The aim of this study is to characterize the anti-inflammatory effects of a novel biologic (InflaMab) that targets the NLRP3 inflammasome and to determine its’ neuroprotective potential in an inducible mouse model of glaucoma.

Methods : InflaMab is a bi-specific antibody that was developed to gain access to the intracellular compartment and target NLRP3. The anti-inflammatory potential of InflaMab was tested in vitro in a THP1 macrophage cell line and murine bone marrow-derived macrophages (BMDMs). IL-1β and TNFα secretion was measured using ELISA and Caspase-1 activation was assessed by staining cells with a Fluorescent Inhibitor of Caspase-1 (FLICA). In vivo, the neuroprotective effect of InflaMab was assessed in a microbead-induced mouse model of glaucoma. WT C57BL/6J mice received one intravitreal injection of InflaMab (250 ng/ml) on Day 0 (just prior to microbead injection). IOP was monitored by rebound tonometry and at Day 28 post microbead injection pattern electroretinogram (pERG) was performed to assess RGC function and retinal whole mounts and optic nerves were prepared for RGC and axon quantification.

Results : In vitro, InflaMab significantly inhibited IL-1β secretion in THP1 cells and BMDMs (p<0.05) and had no inhibitory effect on TNFα production, demonstrating specificity. Confocal microscopy revealed a significant reduction of caspase-1 activation in THP1 cells treated with InflaMab as opposed to non-treated cells. In vivo, a single intravitreal injection of Inflamab provided significant neuroprotection in terms of RGC function (pERG amplitude) and RGC and axon survival when compared to untreated controls

Conclusions : These data demonstrate that (i) InflaMab inhibits inflammasome activation and (ii) intravitreal administration of InflaMab provides sustained neuroprotection in an inducible mouse model of glaucoma.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×